31.6 C
Vientiane
Sunday, May 25, 2025
spot_img
Home Blog Page 103

Phoenix Aviation Capital Acquires one Boeing 787-8 Aircraft on Lease with LOT Polish

DUBLIN and STAMFORD, Conn., May 7, 2025 /PRNewswire/ — Phoenix Aviation Capital (“Phoenix”), a full-service aircraft lessor, and AIP Capital, an alternative investment manager focused on opportunities in in asset-based finance today announced the acquisition of one Boeing 787-8 aircraft on long-term lease with LOT Polish Airways.

The aircraft acquired by Phoenix, bearing manufacturers serial number 35942, is a 2014 vintage Boeing 787-8 powered by Trent 1000 engines. In September 2024, Phoenix had placed four next-generation Boeing 737 MAX 8 aircraft on long-term lease with LOT Polish Airways.

Vinson & Elkins LLP served as transaction counsel and KPMG acted as tax advisor to AIP Capital.

About Phoenix Aviation Capital

Phoenix Aviation Capital is a full-service aircraft lessor focused on financing modern, in-demand aircraft and is dedicated to meeting the financing needs of its airline customers across the globe. Phoenix Aviation Capital is based in Dublin and is managed by AIP Capital, a global aviation asset management and investment firm.

For more information about Phoenix Aviation Capital or to speak with company executives, please contact investor.relations@phoenixaviationcap.com.

About AIP Capital

AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 30 experienced professionals across AIP’s offices in Stamford, New York City, Dublin, and Singapore.

For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com.

Media Contact
AIP Capital
Geoffrey Bayers
investor.relations@aipcapital.com

 

The Walt Disney Company and Miral Announce Plans for Disney Theme Park and Resort on Yas Island, Abu Dhabi

The Seventh Disney Destination Will Extend the Company’s Global Reach and Captivate New Audiences in a Thriving, Dynamic Hub

The Collaboration Exemplifies Abu Dhabi’s Continued Commitment to Sustainable Growth, Positioning Travel and Tourism as Key Pillars of a Thriving Future

ABU DHABI, UAE, May 7, 2025 /PRNewswire/ — The Walt Disney Company (NYSE: DIS) and Miral, Abu Dhabi’s leading creator of immersive destinations and experiences, announced an agreement to create a landmark Disney theme park resort in Abu Dhabi, United Arab Emirates. The waterfront resort will be located on Yas Island, a world-class destination for entertainment and leisure, connecting travelers from the Middle East and Africa, India, Asia, Europe, and beyond. This seventh Disney theme park resort will combine Disney’s iconic stories, characters and attractions with Abu Dhabi’s vibrant culture, stunning shorelines, and breathtaking architecture.

(L-R) Mohamed Al Zaabi, HE Mohamed Al Mubarak, Bob Iger, Josh D’Amaro
(L-R) Mohamed Al Zaabi, HE Mohamed Al Mubarak, Bob Iger, Josh D’Amaro

“Abu Dhabi is a place where heritage meets innovation, where we preserve our past while designing the future,” His Excellency Mohamed Khalifa Al Mubarak, Chairman at Miral, said. “The collaboration between Abu Dhabi and Disney demonstrates the remarkable results of combining visionary leadership and creative excellence. What we are creating with Disney in Abu Dhabi is a whole new world of imagination — an experience that will inspire generations across the region and the world, creating magical moments and memories that families will treasure forever. Through the development of unique attractions and experiences, Abu Dhabi continues to be a destination of choice for the world.”

The new resort will be fully developed and built by Miral. Disney and its legendary Imagineers will lead creative design and operational oversight to provide a world-class experience. Miral, which has developed a number of family entertainment destinations on Yas Island, Abu Dhabi in collaboration with American and European brands, will operate the resort.

“This is a thrilling moment for our company as we announce plans to build an exciting Disney theme park resort in Abu Dhabi, whose culture is rich with an appreciation of the arts and creativity,” said Robert A. Iger, Chief Executive Officer, The Walt Disney Company. “As our seventh theme park destination, it will rise from this land in spectacular fashion, blending contemporary architecture with cutting edge technology to offer guests deeply immersive entertainment experiences in unique and modern ways. Disneyland Abu Dhabi will be authentically Disney and distinctly Emirati – an oasis of extraordinary Disney entertainment at this crossroads of the world that will bring to life our timeless characters and stories in many new ways and will become a source of joy and inspiration for the people of this vast region to enjoy for generations to come.”

The UAE is located within a four-hour flight of one-third of the world’s population, making it a significant gateway for tourism. The UAE is home to the largest global airline hub in the world, with 120 million passengers traveling through Abu Dhabi and Dubai each year.

“This groundbreaking resort destination represents a new frontier in theme park development,” said Josh D’Amaro, Chairman, Disney Experiences. “Our resort in Abu Dhabi will be the most advanced and interactive destination in our portfolio. The location of our park is incredibly unique – anchored by a beautiful waterfront – which will allow us to tell our stories in completely new ways. This project will reach guests in a whole new part of the world, welcoming more families to experience Disney than ever before. Ultimately, it will be a celebration of what’s possible when creativity and progress come together.”

“Bringing a Disney theme park resort to Yas Island marks a historic milestone in our journey to further advance the island’s position as a global destination for exceptional entertainment and leisure,” said Mohamed Abdalla Al Zaabi, Group CEO, Miral. “Together, we are creating a place of boundless innovation, where the vision of our leadership continues to inspire the world.” The development of unique experiences will support sustained economic growth in Abu Dhabi and beyond.

Upon completion, the new theme park resort will offer signature Disney entertainment, themed accommodations, unique dining and retail experiences, and storytelling in a way that celebrates both the heritage of Disney and the futuristic and cultural essence of Abu Dhabi.

Further details will be announced as the project progresses. Please refer to the company’s 10-Q filing today for additional details regarding the agreement.

For downloadable media assets, please visit https://disneyconnect.com/dxpress 

For more information about Miral, visit www.miral.ae.

For more information about Yas Island, please visit https://www.yasisland.com/

Video: https://mma.prnewswire.com/media/2681431/Disney_Theme_Park_Resort_Yas_Island.mp4

Disney Theme Park Resort, Yas Island, Abu Dhabi
Disney Theme Park Resort, Yas Island, Abu Dhabi

 

 

 

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

CHICAGO, May 7, 2025 /PRNewswire/ — Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25–30). The presentations spotlighted novel bispecific antibodies and a CSF-1R inhibitor, underscoring the company’s leadership in innovative cancer treatment strategies.

Key Highlights from HanxBio’s AACR Presentations

1. HX044: A first-in-class (FIC) CTLA-4xSIRPα is a bispecific antibody fusion protein designed to enhance safety and amplify anti-tumor immunity. HX044 targets PD-1-resistant solid tumors (e.g., non-small cell lung cancer, melanoma, renal cell carcinoma). Currently in Phase I trials, it represents a breakthrough in overcoming resistance to existing immunotherapies.

2. HX035: A preclinical OX40-targeting bispecific antibody engineered to address inflammatory and autoimmune diseases. By binding two distinct OX40 epitopes, HX035 aims to achieve best-in-class (BIC) precision in modulating immune responses.

3. HX016-7 & HX016-9: Two preclinical bispecific antibodies targeting PD-L1xVEGF and PD-1xVEGF, respectively. These dual-target therapies aim to disrupt both tumor immune evasion and blood vessel growth (angiogenesis), offering a novel approach to treating solid tumors.

4. HX301 (Narazaciclib): A CSF-1R inhibitor co-developed with Traws Pharma, Inc., now in Phase II trials for glioblastoma. HX301 is being evaluated in combination with temozolomide (TMZ), a standard chemotherapy, to enhance anti-tumor efficacy.

Dr. Henry Li, CEO and CSO of HanxBio, attended and presented posters at the AACR Annual Conference and he emphasized the company’s progress: “Our AACR presentations reflect HanxBio’s commitment to redefining cancer and autoimmune disease treatment through cutting-edge bispecific antibody platforms. With HX044 advancing in clinical trials and a robust preclinical pipeline, we are poised to deliver transformative therapies that address critical unmet needs for patients globally.” He added, “By targeting multiple pathways simultaneously or by exploring coordinated binding (cis-bindings)—we aim to overcome enhanced activity and safety, thus improving outcomes for hard-to-treat cancers.”

About Hanx Biopharmaceuticals, Ltd.

HanxBio is an innovation-driven biotechnology company focused on discovering and developing first-in-class (FIC) and best-in-class (BIC) therapies for cancer and autoimmune diseases. Leveraging expertise in structural biology, translational medicine, and precision clinical development, the company aims to create safe, accessible, and effective treatments that address global health challenges.

For media inquiries, please contact: Info@hanxbio.com 

Chubb Life Hong Kong Launches “Health Up” Insurance Plan to Foster a Wellness Lifestyle for the Tech-savvy Generation


HONG KONG SAR – Media OutReach Newswire – 7 May 2025 – Chubb Life Hong Kong today announced the launch of Health Up Insurance Plan (Health Up), a digital insurance plan aimed at promoting and facilitating well-being practices for individuals wishing to achieve a healthier lifestyle.

Belinda Au(middle), Mercedes Ho (Right), with Health Up Partners
Belinda Au(middle), Mercedes Ho (Right), with Health Up Partners

Health Up is designed to offer term life coverage and accidental death protection1 with a comprehensive suite of health and wellness offers to customers aged 18 to 55. The annual Premium2 of Health Up is HKD800, around HKD2.19 per day, offering exceptional value to health-conscious individuals.

Upon enrollment, customers will receive exclusive access to a wide range of health and wellness offers, provided by health product and service providers such as Comvita, Doctor’s Choice, EC Healthcare, Eu Yan Sang, JP Partners Medical, Naturo Vita, and Vita Green. These services include medical and hearing checkups, dental scaling, and the opportunity to choose supplements such as cordyceps, chicken essence, probiotics, and immune system boosters.

In addition to promoting better health through diet and exercise, Health Up provides a new approach to fostering a healthy lifestyle through allowing customers to select one health and wellness service each year, tailored to their individual wellness needs.

For the younger, tech-savvy generation seeking a convenient, simple and fast digital application experience, Health Up provides an easy application process through Chubb Life Hong Kong’s digital platform. Plus, an exclusive discount is available for MoneyBack App members, one of the largest loyalty programs in Hong Kong, is available along with extra MoneyBack points rewards. Members can redeem a unique promo code through the app and make purchases on Chubb Life’s Health Up webpage to enjoy the offer. There is no requirement for a health examination or financial background check.

Belinda Au, President of Chubb Life Hong Kong and Head of North Asia, said, “We recognise the importance of a comprehensive and holistic approach to personal protection, health, and well-being in today’s environment. With Health Up’s simplicity and seamless online application process, we believe Health Up will encourage our customers to adopt lifestyles that prioritise their personal well-being, and enhance their overall health and wellness.”

To encourage a lifestyle focused on preventive protection, members of Health Up’s partners3 will enjoy a 30% discount using a special promotion code provided by the partners. Alternatively, customers may also access the Health Up webpage via the supporting partners’4 channels to take advantage of a limited-time 30% discount5 available from April 30 to June 30, 2025.

Health up is powered by Chubb Studio, the company’s market-leading global digital integration platform, which created a simple and seamless customer journey for Health Up customers. For more details, please visit: https://ap.studio.chubb.com/v2/hk/chubb/healthup/pweb-healthup/en-HK.

Click here and download for more press photos.

Remarks:

1 While the Policy is in force, the Company will pay the Accident Death Benefit if the Insured sustains an injury which directly and solely results in his / her death within 12 months from the date of Accident.

2 Premiums do not include the levy which is collected by the Insurance Authority. The Premium is not guaranteed, and Chubb Life reserves the right to revise or adjust the Premium according to our applicable Premium rate upon each Policy Anniversary, subject to other terms and conditions, if any, as set out in the Policy.

3 Health Up Partners include Comvita, Doctor’s Choice, EC Healthcare, Eu Yan Sang, JP Partners Medical, Naturo Vita, Vita Green.

4 Supporting Partners included Cosmart, ESD Life, HK01, Midland, Moneyback, Shopback, SportSoho and My TV Super.

5 This limited-time 30% discount is applicable from April 30 to June 30, 2025. Following the promotional period, a standard 20% discount will be reinstated.

“Disclaimer: **Important Note**: Health Up Insurance Plan is an insurance product underwritten by Chubb Life Insurance Hong Kong Limited (“Chubb Life”). As Watson MoneyBack (HK) Limited (“MBHK”) is not a licensed insurance intermediary. MBHK will not advise nor arrange the purchase of any insurance plan or provide any sales support under The Offer. MBHK Program Members hereby acknowledge and agree that they should not rely on any information, recommendation or advice provided by MBHK in making a purchase decision on Chubb Life’s online platform. MBHK is not in any way holding itself out as an insurance agent nor an insurance intermediary. MBHK is not advising, negotiating, arranging, inviting, inducing or attempting to invite or induce the MB Program Members to enter into an insurance contract or to make an application for an insurance contract. MBHK is not in any way attempting to carry out any regulated activities as defined under the Insurance Ordinance (Cap. 41 of Laws of Hong Kong).”

Hashtag: #Chubb

The issuer is solely responsible for the content of this announcement.

About Chubb

Chubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. The company is defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb employs approximately 43,000 people worldwide. Additional information can be found at: .

Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren’s Contracture

– Conducted under U.S. FDA-cleared IND
– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie’s disease

SEOUL, South Korea, May 7, 2025 /PRNewswire/ — Connext, a clinical stage biotechnology company, announced the successful completion of the dose escalation (Phase 1) part of its Phase 1/2 clinical trial for CNT201, its recombinant collagenase therapeutic for Dupuytren’s contracture. The trial was conducted in an open-label format and confirmed both the safety and efficacy of CNT201: no dose-limiting toxicities were observed, and clear therapeutic benefits were demonstrated.

Key Clinical Results and Future Plans

  • The study was conducted under a U.S. FDA-approved IND, using an open-label design to evaluate safety, tolerability, efficacy, pharmacokinetics, and immunogenicity.
  • The dose expansion (Phase 2) part is scheduled to begin in Q3 2025 as a double-blind study, aiming to demonstrate statistically significant efficacy.
  • Top-line data for the entire Phase 1/2 trial are expected in the first half of 2026, with plans to initiate global Phase 3 development in 2027.
  • The latest clinical development of CNT201 will be officially presented at the “International Conference on Dupuytren Disease and Related Diseases” in Brussels in May 2025.

Differentiation Through Innovative Recombinant Collagenase

Currently, Endo’s Xiaflex is the only commercially available collagenase injection for Dupuytren’s contracture. CNT201 is being developed as an alternative to Xiaflex and is expected to significantly improve patient access to non-surgical treatment. Collagenase is originally produced by fermentation of the pathogenic microorganism Clostridium histolyticum, which carries inherent risks of contamination with various toxins. In contrast, CNT201 is the world’s first recombinant collagenase therapeutic developed using genetic engineering technology, eliminating the risk of contamination from toxins or animal-derived substances. This ensures superior quality, consistent efficacy, and differentiated safety profiles.

Expanding Indications and Accelerating Global Drug Development

Connext is also pursuing a Phase 2 IND for Peyronie’s disease, based on the same mechanism of action, and aims to obtain U.S. FDA IND clearance in 2025. Additional development for aesthetic indications such as cellulite is also underway.

Statement from Woo Jong Lee, CEO of Connext

“By confirming both safety and efficacy in the dose escalation part of Phase 1/2 study, CNT201 offers a new non-surgical treatment option for patients with Dupuytren’s contracture. We aim to complete global new drug development with Phase 3 entry in 2027 and demonstrate the unique advantages of our innovative recombinant therapeutic,” said Woo Jong Lee, CEO of Connext.

Contact:
Sangho Lee, Head of Innovation
sangho.lee@connext.co.kr

Ampace Unveils Powerful New Battery System Ahead of Summer Storm Season Offering Week-Long Emergency Power for Families

The Extra Battery Expands Ampace Andes Portable Power Station for Extended Reliability in Any Crisis

LOS ANGELES, May 7, 2025 /PRNewswire/ — Ampace, a leader in lithium-ion power, today unveiled its advanced industrial-grade Ampace Andes 1500 Extra Battery, drastically expanding the capabilities of its flagship Ampace Andes 1500 Portable Power Station. Designed to provide uninterrupted power during emergencies, outdoor adventures, and extended outages, Ampace’s new battery extension arrives just in time for the anticipated summer storm season, ensuring families are never left in the dark.

Ampace Andes 1500 Extra Battery
Ampace Andes 1500 Extra Battery

Equipped with premium RESS (Residential Energy Storage System)-grade battery cells with a capacity of 1,462Wh at just 13kg, the system works seamlessly with the Ampace Andes 1500 Portable Power Station and supports connection of up to seven extended batteries, achieving a total capacity of 11,696Wh—enough to power an average household for up to a full week.

This cutting-edge battery system can sustain critical home appliances, high power tools and more—keeping entire households operational for up to a full week. The timing of this launch is particularly crucial, as weather forecasters predict a heighted frequency of severe weather events this year.

“At Ampace, we understand that dependable power isn’t just convenience, it is a necessity,” said Alfonso Chen, CMB Director of Ampace. “With Ampace Andes 1500 Extra Battery, we offer more than just power; we are providing peace of mind and potentially lifesaving reliability for thousands of families preparing for unexpected events.”

Like the Ampace Andes 1500 Portable Power Station, the Andes 1500 Extra Battery is built with RESS-grade battery cells, delivering exceptional portability without compromising on safety—setting a new standard for reliable power expansion. With industry-leading 55-minute rapid recharge technology and an extraordinary 6,000-cycle lifespan, it ensures like-new performance for over 15 years, even under intensive use.

Its rugged design withstands harsh temperatures (–4°F to 113°F) and includes a state-of-the-art mobile app for real-time monitoring, empowering users to manage their power needs seamlessly, whether sheltering at home during a storm or exploring off-grid adventures.

Featuring a built-in display, users can monitor the remaining battery level and charging time in real-time. The device includes integrated cable storage, keeping charging cords neatly organized and saving space. Its dual-handle design ensures effortless portability. Furthermore, the ports are equipped with foolproof protection to prevent incorrect connection.

The Ampace Andes 1500 Extra Battery is available now on Amazon for $599 or bundled with the Ampace 1500 Portable Power Station for $1,249. More details can be found at ampacepower.com.

About Ampace

Ampace Technology Limited (hereinafter referred to as “Ampace”) stands as a globally acclaimed innovator in new energy technologies, committed to delivering green energy solutions with ultimate user experience to forge the world ahead and empower a better life. In the realm of energy storage, e-mobility, power tools, vacuum cleaners, drones, and more, Ampace has established extensive strategic partnerships with industry leaders. The company is renowned for providing new energy products and services characterized by ultimate safety, reliability, performance, and user experience, serving over 50 million customers in 30 countries and regions worldwide.

About Ampace Andes

Ampace Andes is the flagship portable power brand under Ampace, built for extremes. Powered by over 20 years of innovation from Ampace—a global leader in energy storage—Ampace Andes delivers rugged, high-performance solutions designed to withstand the harshest environments. Whether in freezing cold or remote locations, Ampace Andes keeps your devices powered and your adventures going. Andes is more than a power station—it’s your dependable partner in facing the unpredictable. Ampace Andes — Powering the Extremes.

Contact: Xiaoning Chen, chenxn@ampacetech.com 

EcoFlow Launches STREAM Series, the First U.S. Plug-and-Play Home Solar System Designed for Apartments and Condos in Addition to Single Family Homes

STREAM Series lets more people than ever enjoy solar power’s benefits of lower utility bills and home backup energy with an easy DIY setup

SEATTLE, May 7, 2025 /PRNewswire/ — EcoFlow, a leading portable power and eco-friendly energy solutions company, today introduces STREAM Series, the first plug-and-play home solar system available in the U.S. with a battery that can power your home.

Designed for homes with backyards, multifamily apartments and condos, STREAM Series can help cut electricity bills by harnessing solar energy for daily use. The system can be purchased with or without a battery. The battery version, STREAM Ultra, helps maximize energy savings and can provide critical backup power during a blackout.

STREAM will be available in Utah at launch, with plans to roll out this new product category in other states in the future. Utah’s rising electricity rates, strong solar potential and growing percentage of multi-family dwellings make STREAM Series a great option for residents seeking a plug-and-play, DIY solar solution with no installation, no complex setup and no utility approval needed.

“By launching Stream Series in Utah, we’re taking the first step in making renewable energy simple and accessible for people in the U.S. who have not been able to enjoy the benefits of residential solar,” said Brian Essenmacher, head of North American business development at EcoFlow.

“We’ve successfully launched this solution across Europe over the past two years with more than 120,000 units sold,” Essenmahcer said. “We’re now applying our global experience to bring flexible solar options to Americans beyond just single family homes. Plug-and-play home solar systems allow people to save on electric bills while avoiding the high costs, permitting and months-long installation timelines of traditional systems.”

How Does STREAM Series Work?

The EcoFlow STREAM series includes two key products: STREAM Ultra and STREAM Microinverter. The STREAM Ultra is a 1.92kWh solar battery with a built-in grid-tied microinverter — the first of its kind in the industry. The Microinverter converts solar energy directly into grid-ready electricity without energy storage capability.

The STREAM Ultra battery maximizes energy savings by storing excess solar power collected during daylight hours and making it available for regular use later or in the event of a power outage. STREAM Ultra can also collect 2000W of solar input, with 1,200W being directly fed into your home via the built-in microinverter, while any excess energy is stored in the battery.

For homes without energy storage needs, the optional standalone STREAM Microinverter converts solar energy directly into the home via a standard AC wall outlet up to 1,200W output. This energy is instantly available for use, helping to lower reliance on the grid and reduce utility bills.

This flexible system allows residents to position solar panels on balconies, patios, backyards and other outdoor spaces and harness their power in three configurations:

  • STREAM Ultra: Up to 2,000W of total solar input with up to 1,200W of it going directly to the home and the remainder for battery charging.
  • STREAM Microinverter: Up to 1,200W of solar power going directly to the home.
  • STREAM Ultra + STREAM Microinverter: Up to 3,200W of total solar input with up to 1,200W going directly to the home and up to 2,000W for battery charging.

Ultimate Electricity Cost Savings & Expandability

With one EcoFlow STREAM Ultra and one Microinverter, this plug-and-play setup can provide more than 6,000kWh of electricity per year, supplying approximately half of the average U.S. household’s needs and cutting bills by as much as $1,027 annually [note].

When multiple Ultra batteries are connected, the modular setup can expand from 1.92kWh to 11.52kWh and allows flexible battery placement. Powered by an AI-driven solar network, multiple batteries can work in sync — no matter where they’re located — to extend runtime, minimize grid reliance and eliminate solar waste. With its plug-and-play setup and intelligent energy flow management, households move closer to energy independence and zero electricity bills.

Smart Design. Smarter Energy Management

Built for long-lasting performance and everyday ease, STREAM Series features a clean, compact design that integrates seamlessly into modern homes. STREAM Ultra’s durable LFP battery retains 70% capacity even after 6,000 cycles and operates reliably in extreme temperatures down to -14°F. With a NEMA 4 rating for the Ultra battery and NEMA 6 for the Microinverter, the system is built to handle both indoor and outdoor conditions. Built-in safety mechanisms continuously monitor energy loads in real time, automatically adjusting power to stay within the 1200W limit and prevent tripping household circuits.

The STREAM Series is compatible with EcoFlow OASIS, an AI-powered energy management platform available through the EcoFlow app, designed to maximize home energy storage, prepare for weather-related power outages and reduce electric bills.

EcoFlow OASIS tracks real-time usage, generates detailed power usage reports, automatically optimizes charging based on Time-of-Use electricity pricing and provides smart recommendations to help lower costs. It also includes a multilingual 24/7 AI assistant that keeps users informed and in control and can answer product-related questions. With this intelligent layer, users gain full visibility and control over their energy production and consumption, making smarter energy decisions easier than ever.

Pricing & Availability

EcoFlow’s STREAM Series will be available for pre-order starting May 7 at an early-bird price, with official availability launching on July 14. To take advantage of the early-bird price, simply sign up with your email between May 7 and July 14. The early-bird offer will be valid until July 31.

*With dedicated 15A circuit.

Product

Early-Bird Price

MSRP

STREAM Ultra (battery)

$1199

$1899

STREAM Microinverter

$299

$599

STREAM Ultra and Microinverter

$1459

$2399

About EcoFlow:

EcoFlow is a leading provider of eco-friendly energy solutions, committed to powering a new world. Since its founding in 2017, EcoFlow has aimed to be the FIRST in power solutions — Flexible, Innovative, Reliable, Simple, and Thorough — for individuals and families, whether at home, outdoors or on the go. With a smart manufacturing center in China, and headquarters in the USA, Germany and Japan, EcoFlow has empowered over 5 million users in 140 markets worldwide. For more information, visit https://www.ecoflow.com/us.

Lunit to Power Germany’s Largest Private Radiology Network with AI Imaging

The five-year framework agreement covers phased rollout of Lunit’s AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites

SEOUL, South Korea, May 7, 2025 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a strategic partnership with Starvision Service GmbH, Germany’s largest private radiology network. Through a newly signed framework agreement, Lunit’s AI imaging solutions will be deployed across Starvision’s expansive network of radiological practices.

Executives from Lunit and Starvision Service GmbH commemorate the signing of a supply agreement at the recent European Congress of Radiology (ECR 2025). From left to right: Dominik Guenzel, Regional Manager for DACH and Scandinavia at Lunit; Uwe Pfeifer, CEO of Starvision; Brandon Suh, CEO of Lunit; and Teri Thomas, Chief Business Officer at Lunit. (Photo: Lunit)
Executives from Lunit and Starvision Service GmbH commemorate the signing of a supply agreement at the recent European Congress of Radiology (ECR 2025). From left to right: Dominik Guenzel, Regional Manager for DACH and Scandinavia at Lunit; Uwe Pfeifer, CEO of Starvision; Brandon Suh, CEO of Lunit; and Teri Thomas, Chief Business Officer at Lunit. (Photo: Lunit)

Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH healthcare market, Starvision is known for its commitment to digital transformation, operational excellence, and high-quality patient care.

Under the agreement, Starvision will adopt several of Lunit’s AI solutions, including:

  • Lunit INSIGHT CXR: AI-based chest X-ray analysis
  • Lunit INSIGHT MMG: Mammography analysis solution
  • Lunit INSIGHT DBT: Digital breast tomosynthesis interpretation
  • RBfracture: AI-driven fracture detection

The first commercial deployments are already underway—including use of Lunit INSIGHT MMG at Radiologische Allianz in Hamburg, supporting the Hamburg breast cancer screening program under the Starvision network. Together with deployments at Die Radiologie, a major regional hospital group operating over 20 medical sites across Bavaria, Lunit’s solutions are now supporting approximately 120,000 breast cancer screenings and diagnoses annually across the two institutions.

The five-year framework agreement allows additional Starvision locations—and newly affiliated practices—to join at any time, enabling broad scalability across the network. New deployments and clinical trials are already in progress, with individual agreements being signed across Starvision’s entities as part of a phased implementation plan. Beyond Starvision, several other healthcare providers across Germany have also expressed interest, reflecting the expanding demand for AI-driven imaging solutions.

“Lunit’s AI solutions support our radiologists in delivering fast and accurate diagnoses. This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients,” said Uwe Pfeifer, CEO of Starvision Service GmbH.

“Partnering with Starvision accelerates our vision of bringing AI-powered precision diagnostics into everyday clinical practice,” said Brandon Suh, CEO of Lunit. “Together, we are advancing a new era of radiology where technology enhances the expertise of physicians, delivering better outcomes for millions of patients in Germany and beyond.”

The partnership supports both companies’ vision of transforming healthcare through intelligent technology and setting new standards in radiology.

###

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit’s FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.